7-Keto-dehydroepiandrosteroneCAS# 566-19-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 566-19-8 | SDF | Download SDF |
| PubChem ID | 193313 | Appearance | Powder |
| Formula | C19H26O3 | M.Wt | 302.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-2,3,4,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-7,17-dione | ||
| SMILES | CC12CCC3C(C1CCC2=O)C(=O)C=C4C3(CCC(C4)O)C | ||
| Standard InChIKey | KPRGOTLNGIBVFL-GINZOMEDSA-N | ||
| Standard InChI | InChI=1S/C19H26O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-14,17,20H,3-9H2,1-2H3/t12-,13-,14-,17-,18-,19-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
7-Keto-dehydroepiandrosterone Dilution Calculator
7-Keto-dehydroepiandrosterone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.3069 mL | 16.5344 mL | 33.0688 mL | 66.1376 mL | 82.672 mL |
| 5 mM | 0.6614 mL | 3.3069 mL | 6.6138 mL | 13.2275 mL | 16.5344 mL |
| 10 mM | 0.3307 mL | 1.6534 mL | 3.3069 mL | 6.6138 mL | 8.2672 mL |
| 50 mM | 0.0661 mL | 0.3307 mL | 0.6614 mL | 1.3228 mL | 1.6534 mL |
| 100 mM | 0.0331 mL | 0.1653 mL | 0.3307 mL | 0.6614 mL | 0.8267 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-Hydroxy-2-phenyl-propanamide
Catalog No.:BCN3905
CAS No.:56598-62-0
- PIT
Catalog No.:BCC7151
CAS No.:56583-49-4
- (-)-Bornyl acetate
Catalog No.:BCN2636
CAS No.:5655-61-8
- Cyclo(Pro-Val)
Catalog No.:BCN2420
CAS No.:5654-87-5
- Cyclo(Pro-Leu)
Catalog No.:BCN2426
CAS No.:5654-86-4
- Cyclo(Tyr-Pro)
Catalog No.:BCN2421
CAS No.:5654-84-2
- 2-Hydroxy-3,4-dimethoxybenzoic acid
Catalog No.:BCN6535
CAS No.:5653-46-3
- Angelic acid
Catalog No.:BCN3410
CAS No.:565-63-9
- Steppogenin
Catalog No.:BCN5760
CAS No.:56486-94-3
- 4,9-Dihydroxy-alpha-lapachone
Catalog No.:BCN5758
CAS No.:56473-67-7
- Eichlerianic acid
Catalog No.:BCN5757
CAS No.:56421-13-7
- Methyl eichlerianate
Catalog No.:BCN5756
CAS No.:56421-12-6
- 7Beta-Hydroxycholesterol
Catalog No.:BCN2751
CAS No.:566-27-8
- Formestane
Catalog No.:BCC4369
CAS No.:566-48-3
- BOP reagent
Catalog No.:BCC2807
CAS No.:56602-33-6
- H-D-Phe(4-NO2)-OH
Catalog No.:BCC3274
CAS No.:56613-61-7
- D-Phenylglycinol
Catalog No.:BCC2712
CAS No.:56613-80-0
- Z-Arg-OH.HCl
Catalog No.:BCC3061
CAS No.:56672-63-0
- Batatasin III
Catalog No.:BCN3596
CAS No.:56684-87-8
- 2-Benzylacrylic acid
Catalog No.:BCC8564
CAS No.:5669-19-2
- Orteronel
Catalog No.:BCC1823
CAS No.:566939-85-3
- (+/-)-Vestitol
Catalog No.:BCN6814
CAS No.:56701-24-7
- Z-Glu-OMe
Catalog No.:BCC2779
CAS No.:5672-83-3
- Icariside I
Catalog No.:BCN3463
CAS No.:56725-99-6
The clinical use of dehydroepiandrosterone in postmenopausal women.[Pubmed:23965649]
Int J Pharm Compd. 2010 Nov-Dec;14(6):465-71.
A basic understanding of the distinct metabolism, mechanism of action, and clinical use of dehydroepiandrosterone and its metabolites is critical to balancing the hormone milieu in postmenopausal women. To date, studies of dehydroepiandrosterone therapy in women with adrenal insufficiency suggest that they are the most likely group to gain health benefits from dehydroepiandrosterone replacement therapy. Our understanding of the potential long-term health benefits of replacing dehydroepiandrosterone along with other deficient hormones is still only in its infancy. With the evidence currently available, however, one can reasonably suggest that dehydroepiandrosterone offers the promise of a safe and efficient replacement therapy for specific symptoms common to postmenopausal women. This article reviews the metabolism, physiology, and clinical use of dehydroepiandrosterone in postmenopausal women. The clinical effectiveness of dehydroepiandrosterone for vulvovaginal atrophy, sexual dysfunction, osteoporosis, adrenal and immunological function, cardiovascular disease, and, in combination, hormone replacement therapy is reviewed. In addition, the use of the dehydroepiandrosterone metabolite 7-Keto-dehydroepiandrosterone for weight loss is discussed.
[Effect of chorionic gonadotropin on the urinary excretion of testosterone and other androgens in healthy men and those with coronary arteriosclerosis].[Pubmed:156806]
Kardiologiia. 1979 Jun;19(6):76-9.
The results of studying the excretion of testosterone and other androgens with the urine after a chorionic gonadotropin load in patients with ischemic heart disease and in persons who had suffered from acute myocardial infarction are discussed. In choriogonin load stimulating the gonads, there is noticeable variability in the excretion of testosterone and epitestosterone, androstenedione, and 7-Keto-dehydroepiandrosterone in the urine. The data obtained are evidence of reduced functional reserves of the sex glands in some of the patients.
